Sanofi Continues Global Employee Shareholder Programme as Nearly 90,000 Current and Former Staff Hold Company Shares

(IN BRIEF) Sanofi is launching its 2026 global employee stock purchase plan, Action 2026, giving approximately 75,000 eligible employees in 52 countries the opportunity to invest in the company. The programme opens from June 9 to June 29, 2026, and offers shares at a subscription price of €59.87, representing a 20% discount on the average of Sanofi’s 20 opening share prices between May 6 and June 2, 2026. Employees will also receive one free matching share for every five shares subscribed, up to a maximum of four matching shares per employee. The initiative, now in its 12th year, reflects Sanofi’s continued focus on employee ownership and long-term alignment with the company’s growth. In 2025, more than 31,000 employees, or 44% of Sanofi’s workforce, participated in the programme. Today, nearly 90,000 current and former Sanofi employees hold shares representing approximately 2.93% of the company’s capital. The new share issue is expected to be completed by the end of July 2026, with up to 9,816,701 shares offered, subject to eligibility, legal limits and local regulatory requirements.

(PRESS RELEASE) PARIS, 4-Jun-2026 — /EuropaWire/ — Sanofi has announced the opening of its 2026 global employee stock purchase plan, Action 2026, continuing its long-running effort to give employees the opportunity to share in the company’s growth and performance.

The plan will open on June 9, 2026, and will be available to approximately 75,000 eligible Sanofi employees across 52 countries. Now entering its 12th year, the programme reflects Sanofi’s continued commitment, supported by its Board of Directors, to strengthening employee ownership and aligning employees more closely with the company’s long-term development.

Employee participation in the programme has continued to grow. In 2025, more than 31,000 Sanofi employees, representing 44% of the company’s workforce, chose to invest in Sanofi through the plan. Today, nearly 90,000 current and former employees are Sanofi shareholders, together holding approximately 2.93% of the company’s share capital.

Belén Garijo, Chief Executive Officer of Sanofi, said the rising participation in the global employee share purchase plan reflects employees’ confidence in Sanofi’s transformation and their pride in contributing to the company’s progress. She added that this trust is a major asset as Sanofi continues to execute its strategy and maintain its position in the biopharmaceutical sector.

Under Action 2026, eligible employees will be able to subscribe for Sanofi shares between June 9 and June 29, 2026. The subscription price has been set at €59.87 per share, representing a 20% discount on the average of the 20 opening share prices recorded between May 6 and June 2, 2026.

The plan also includes a matching share component. For every five shares subscribed, employees will receive one free matching share, up to a maximum of four matching shares per employee. Each eligible employee may purchase up to 1,500 Sanofi shares, subject to legal limits. The total payment amount may not exceed 25% of the employee’s gross annual salary, after deducting any voluntary contributions already made during 2026 to certain employee savings schemes, including the Company savings plan, Group savings plan and Group retirement savings plan, while voluntary contributions to the separate PERCOL are not included in this limit.

To participate, employees must meet an eligibility condition of three months’ employment by the closing date of the offer period. The share issue is expected to be completed, with delivery of the securities, by the end of July 2026. The total number of shares offered under the plan is limited to 9,816,701 shares.

The new shares, including matching shares, will be subscribed or delivered either directly or through employee mutual funds known as FCPEs, depending on the regulations and tax framework applicable in each eligible employee’s country of residence. The shares will rank equally with Sanofi’s existing ordinary shares and will carry dividend rights from the date of issuance.

Voting rights attached to the subscribed shares will be exercised directly by employees. In France, shares and corresponding FCPE units subscribed through the Sanofi Group savings plan must generally be held until May 31, 2031, except in cases of early release permitted under the French Labor Code. For shares subscribed outside France through the Sanofi International group shareholding plan, the holding period may be shortened to three years, until May 31, 2029, depending on local legal and tax conditions.

Sanofi will request admission of the new shares to trading on Euronext Paris under ISIN code FR0000120578, on the same listing line as the company’s existing shares, as soon as possible after completion of the capital increase.

The offer will only be made in countries where all required registration, notification, approval, employee consultation and information procedures have been completed, or where an exemption from prospectus or registration requirements applies. The announcement does not constitute an offer to sell or a solicitation to buy Sanofi shares. It is also not intended for distribution in countries where the necessary approvals or exemptions are not available or where required formalities remain incomplete, including Japan, Morocco and the Philippines, where procedures with the authorities are still pending.

This communication has been prepared under the relevant exemption from publication of a prospectus under Article 1 4°i) and 5°h) of the Prospectus Regulation (EU) 2017/1129 and serves as the required document for that exemption.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Sanofi Continues Global Employee Shareholder Programme as Nearly 90,000 Current and Former Staff Hold Company Shares

About EuropaWire

SEARCH 35,000+ EUROPEAN PRESS RELEASES

PRs by Dates

Industries & Countries

Archived PRs

Recent PRs

POPULAR TAGS

Links